The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

The incidence of adverse events was similar among study groups (placebo = 84.6%, levetiracetam 2000 mg/day = 83.3%, levetiracetam 4000 mg/day = 84.2%) in the double-blind treatment period.

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic ...

CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity, today announced topline int ...

The FCM protein snack bar, rich in amino acids and antioxidants, improves brain function and memory accuracy in just six ...

Source Reference: Janik A, et al "Efficacy and safety of esketamine nasal spray as monotherapy in adults with ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

"Calluna completes CAL101 Phase I clinical study for fibrotic conditions" was originally created and published by Clinical ...

MGT-GAD-025 is a 6-month, three-arm, randomized, double-blind, sham-controlled study using AAV-GAD drug product manufactured by MeiraGTx at its wholly-owned facilities with its commercial platform ...